All Phenotypes Slc28a1<em1Govr> MGI Mouse

mortality/aging ( J:336148 )

N	• despite anemia no increase in mortality is seen at any age

anemia ( J:336148 )

• less severe than in Slc29a3 null mice

decreased erythrocyte cell number ( J:336148 )

• at 20 weeks of age

decreased hematocrit ( J:336148 )

• at 20 weeks of age

reticulocytosis ( J:336148 )

• compensatory increase in the number of reticulocytes and differential reticulocyte count at 20 weeks of age

homeostasis/metabolism phenotype ( J:336148 )

N	• albuminuria is not observed and average urinary creatinine levels are similar to controls

• increased serum creatinine at 20 weeks of age

abnormal urine nucleoside level ( J:336148 )

• elevated levels of pyrimidine (deoxy)nucleosides (uridine, cytidine, deoxyuridine, deoxycytidine, and deoxythymidine) in the urine

• however, levels of purine (deoxy)nucleosides are not significantly different

abnormal metabolism ( J:336148 )

• significant changes to both the urine and plasma metabolomes related to changes in purine and pyrimidine metabolism

• decreased plasma levels of nucleoside drugs due to increased urinary loss

• decreased therapeutic efficacy of anticancer drug gemcitabine that can be compensated by increasing the dose

abnormal urine nucleoside level ( J:336148 )

• elevated levels of pyrimidine (deoxy)nucleosides (uridine, cytidine, deoxyuridine, deoxycytidine, and deoxythymidine) in the urine

• however, levels of purine (deoxy)nucleosides are not significantly different

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 08/02/2024 MGI 6.24